Replies to post #114071 on Biotech Values

[DewDiligence]

…the same 30mg syringes in the hospital Box of 10 $187 (Sandoz) vs $130 per box (SNY).

Is there a typo in this sentence? You have Sandoz charging substantially more than SNY for this SKU.

Thanks for your post and welcome to the board. Regards, Dew

[joethdo]

Thanks for your post.

So you're implying that TEVA really did think that approval was imminent?

[dewophile]

mnta

thanks for the posts and welcome to the board

This is how SNY maintained 85% mkt shr in the hospitals.

i don't see how this can be when sandoz states they are at or above 40% market share. even if sandoz is wrong sanofi divulged that they have 67% share by volume during their Q3 call. so even if you assume sny's share as dollar share (and there are myriad other data points not too - not the least of which SNY disclosed what they felt was the impact of generic enox at 208M euro so clearly more than 33% by dollars), that means mL would have to have had 60% market share in retail in Q3 if the market is divided by volume 40% retail 60% hospital.* we know from IMS they didn't have that even by end of Q3, and i believe by volume retail is only 30% market share

so either the 85% figure is off, or mL has <33% market share (more like 20-25%)
we know pricing discounts aren't the issue based on what you quoted

*edit 60x.4 + 15x.6 = 33

[EyeamBill]

Sandoz is only getting the 30,40mg business as far as I know in the retail setting.

While "only" is a strong word I do agree with the gist of your point. At least until February 28th, after which time Sandoz m-Enox will be a player in the higher and just as importantly twice-as-frequent dosing.

What's more, these things tend to snowball and I wouldn't be surprised if other GPOs are picked off one-by-one. Maybe Teva should have stopped poking the bear with a stick, huh?

Sorry I didn't see your post regarding the HPG news first. I hadn't read it until after I had posted. I would have probably saved everybody my lengthy preamble had I known it was reported previously.

Bill